U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma Pharmaceutical Investing
Candyverse Brands Inc. Receives Strong January Purchase Orders for its Better Bears Products Life Science Investing
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor Pharmaceutical Investing
BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer Life Science Investing
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy Pharmaceutical Investing
BioHarvest Sciences Inc. Trademarks Its Breakthrough Non-GMO Proven Platform Technology: "BIO-PLANT CELLicitation" Life Science Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
